A Danish trial of 330,000+ adults ≥65 found high and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
From chikungunya setbacks to COVID-19 booster guidance and childhood vaccine safety initiatives, here are the top regulatory and research developments this summer.